Last mentioned: Mar 6, 2026
Scheduled Re-evaluation
NICE appraisal committee is set to meet for a second round of evidence review.
Expected Appeal Date
Final appraisal committee meeting to review new evidence and potential Managed Access Agreements.
Public Campaign Launch
Bereaved family launches a national campaign imploring the NHS to reconsider the approval.
National Campaign Launch
Bereaved family and patient advocates launch a coordinated media campaign imploring the NHS to reconsider.
NICE Initial Review
NICE issues a preliminary recommendation against the drug due to cost-effectiveness concerns.
NICE Initial Review
NICE issues a preliminary recommendation against routine funding based on cost-effectiveness.
MHRA Approval
The drug receives safety and efficacy licensing for use in the UK market.
FDA Approval
The treatment receives accelerated approval in the United States for aggressive cancer types.
A bereaved family's national campaign has ignited a fierce debate over the NHS's refusal to fund a new treatment for aggressive cancer despite evidence of significant tumor shrinkage. The case underscores the growing tension between rapid pharmaceutical innovation and the UK's rigid cost-effectiveness appraisal frameworks.
A bereaved family's public campaign has reignited a national debate over the NHS's drug appraisal process for aggressive cancers. The movement highlights the growing tension between fiscal cost-effectiveness and the urgent need for life-extending therapies already available in other markets.